Clinical trials · Rochester, NY
Acute Leukemia clinical trials in Rochester
We’re tracking 27 recruiting acute leukemia studies with a site in or near Rochester — including Early Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Rochester
- NCT06697600Recruiting
Supporting decisions for older adults with AML and their caregivers
This study helps older adults with newly diagnosed acute myeloid leukemia (AML) and their caregivers make informed decisions about treatment. You and a caregiver (like a family member or friend) will get extra support to talk through your options.
Rochester, New YorkAges 60 years+ - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Rochester, New YorkAges Up to 12 months - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Rochester, New YorkAges 18–59 - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Rochester, New YorkAges 12 months–25 years - NCT05732103RecruitingPhase 1/Phase 2
Testing CTX-712 for AML or high-risk MDS after prior treatment
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
Rochester, New YorkAges 18 years+ - NCT06852222RecruitingPhase 3
Study of bleximenib, venetoclax, and azacitidine for newly diagnosed AML
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Rochester, New YorkAges 18 years+ - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Rochester, New YorkAges 18–39 - NCT05429632RecruitingPhase 3
Mocravimod to prevent relapse after bone marrow transplant for AML
This Phase 3 trial tests mocravimod, added to standard care, to help keep acute myeloid leukemia (AML) from coming back after an allogeneic bone marrow (stem cell) transplant. It may help by supporting long-term remission during the transplant recovery period.
Rochester, New YorkAges 18–75 - NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Rochester, New YorkAges 18 years+ - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Rochester, New YorkAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Rochester, New YorkAges 18–59 - NCT06773936Enrolling by invitationPhase 2
Adding asciminib to usual care for adults with newly diagnosed Ph+ ALL
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
Rochester, New YorkAges 60 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Rochester, New YorkAges 18 years+ - NCT04546399RecruitingPhase 2
Blinatumomab with or without nivolumab for first relapse ALL
This study compares blinatumomab alone versus blinatumomab plus nivolumab in young people whose B-cell ALL has returned for the first time. It aims to see whether adding nivolumab improves control of the leukemia after relapse.
Rochester, New YorkAges 1–30 - NCT03016806Recruiting
Umbilical cord blood transplant from unrelated donors
This trial studies transplanting healthy blood-forming cells from an umbilical cord blood donor who is not related to you. It may help people with certain blood cancers, immune disorders, or other serious diseases when a standard transplant plan is needed.
Rochester, New YorkAges 2 months–75 years - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Rochester, New YorkAges Any age - NCT05554393RecruitingPhase 2
Treating intermediate-risk AML in younger adults
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
Rochester, New YorkAges 18–59 - NCT04315324RecruitingPhase 1/Phase 2
Test drug OBI-3424 for relapsed T-cell blood cancer
This trial tests OBI-3424, an investigational medicine, in adults and children with relapsed or hard-to-treat T-cell acute leukemia or certain T-cell lymphoma. It may help by shrinking cancer when standard treatments have not worked.
Rochester, New YorkAges 12 years+ - NCT04293562RecruitingPhase 3
Testing targeted drugs plus chemo for newly diagnosed AML
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Rochester, New YorkAges Up to 21 years - NCT01311258Recruiting
Tracking leftover cancer cells in AML or high-risk MDS
This study checks for “minimal residual disease,” meaning tiny numbers of leukemia cells that can remain after treatment. Results may help doctors better monitor your response and risk of relapse in AML or high-risk MDS.
Rochester, New YorkAges 18 years+ - NCT03964506RecruitingEarly Phase 1
Hyperbaric oxygen plus donor stem cell transplant for blood cancers
This early-phase trial studies whether breathing pure oxygen in a pressurized chamber, along with a donor stem cell transplant, can improve outcomes for certain blood cancers. It may help by supporting the body during transplant and recovery, but it is still being tested for safety and effectiveness.
Rochester, New YorkAges 18–75 - NCT05237258Recruiting
Compare palliative care approaches for people with high-risk AML
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Rochester, New YorkAges 18–120 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Rochester, New YorkAges Up to 22 years - NCT05875805Recruiting
Telehealth planning for future care decisions
This trial tests a telehealth (video or phone) program that helps people with certain blood cancers plan their future care preferences. It may help you and your chosen support person communicate your wishes clearly, especially if you become too sick to speak for yourself.
Rochester, New YorkAges 60 years+
Hear when a new Acute Leukemia trial opens near Rochester, NY
We’ll email you when one opens near Rochester, NY — at most once a week, no account needed, unsubscribe anytime.
Acute Leukemia trials in other cities
Where these studies are running near Rochester
Institutions with a site for the recruiting acute leukemia studies listed above.
- University of Rochester · 16 studies
- University of Rochester Medical Center · 4 studies
- Wilmot Cancer Institute · 3 studies
- Rochester General Hospital
- Strong Memorial Hospital
What taking part in a acute leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting acute leukemia studies in New York.
Common questions
- Are there acute leukemia clinical trials near Rochester?
- Yes. We're currently tracking 27 recruiting acute leukemia studies with a site near Rochester, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a acute leukemia study near Rochester?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Rochester to take part?
- Not necessarily. These studies have a site near Rochester, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a acute leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New acute leukemia studies open near Rochester regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.